Screener
Oruka Therapeutics, Inc. ORKA Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development(1) | $29,145 | $19,925 |
| General and administrative(2) | 7,289 | 5,161 |
| Total operating expenses | 36,434 | 25,086 |
| Loss from operations | (36,434) | (25,086) |
| Other income (expense): | ||
| Interest income | 4,606 | 4,092 |
| Other income (expense), net | 8 | (5) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s acquired in-process research and development?
- Oruka Therapeutics, Inc. (ORKA) reported acquired in-process research and development of $29.15M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s acquired in-process research and development changed year-over-year?
- Oruka Therapeutics, Inc.'s acquired in-process research and development increased by 46.3% year-over-year, from $19.93M to $29.15M.
- What does acquired in-process research and development mean?
- Represents cash outflows for the acquisition of in-process research and development projects from third parties. This metric reflects a company's strategy to supplement internal innovation pipelines through external asset purchases rather than organic development.
Ask your AI about Oruka Therapeutics, Inc.'s acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude